Pacira BioSciences
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health...
Latest News
5 days ago · prnewswire.com
Ingram Micro Holding Set to Join S&P SmallCap 600NEW YORK, Nov. 11, 2026 /PRNewswire/ -- Ingram Micro Holding Corp. (NYSE: INGM) will replace Pacira BioSciences Inc. (NASD: PCRX) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, November 17. S&P 500 constituent Viatris Inc. (NASD: VTRS) is acquiring Pacira BioSciences in a deal expected to close soon, pending final closing conditions.
17 days ago · businesswire.com
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its ShareholdersNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Pacira and its board of directors violated t.
3 months ago · zacks.com
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook CutPCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.
3 months ago · seekingalpha.com
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call TranscriptPacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
3 months ago · zacks.com
Pacira (PCRX) Tops Q2 Earnings and Revenue EstimatesPacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.74 per share a year ago.
3 months ago · globenewswire.com
Pacira BioSciences Reports Second Quarter 2026 Financial Results-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.
4 months ago · globenewswire.com
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — BRISBANE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has successfully transitioned PCRX-201 (enekinragene inzadenovec), its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based scalable commercial manufacturing process intended to support future registrational development and commercialization.
4 months ago · globenewswire.com
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
7 months ago · globenewswire.com
PharmaCorp Completes Acquisition of Pharmacy Files in Western CanadaSASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, is pleased to announce the completion of its acquisition from an arm's length vendor (the “Vendor”) of the prescription files, patient records and related operational data (collectively, the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp's existing PharmaChoice-bannered pharmacies in Western Canada (the “Acquisition”). The purchase price for the Acquisition was $300,000, subject to customary adjustments, and was satisfied with cash on hand. No finder's fees were payable in connection with the Acquisition.
7 months ago · zacks.com
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YPCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PCRX